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Cardiac amyloidosisdan underdiagnosed cause of
heart failure in the elderly
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a
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Abstract
Amyloidosis is a rare, generally multisystem disease that can also involve the heart. Inﬁltration of the myocardium
with amyloid proteins is an important and underappreciated cause of heart failure with preserved ejection fraction in the
elderly. We present the case of an 84-year-old man with chest tightness, dyspnoea, and ascites. He had a history of
dyslipidaemia and ischaemic heart disease. Initial investigations showed severe diastolic dysfunction and elevated
pulmonary artery systolic pressure on echocardiogram along with elevated serum natriuretic peptides. Further evaluation by a magnetic resonance imaging scan of the heart and endomyocardial biopsy conﬁrmed the diagnosis of senile
systemic amyloidosis. He made good progress after treatment with conventional heart failure drugs and is currently
under consideration to start on speciﬁc medications to slow down the progression of amyloidosis. This case aims to
increase clinicians’ awareness of senile amyloidosis as a cause of heart failure in the elderly.
Keywords: Diastolic dysfunction, Elderly, Heart failure, Inﬁltrative cardiomyopathy, Senile amyloidosis

1. Learning points
 Cardiac amyloidosis is an underappreciated
cause of heart failure in the elderly.
 Evidence of ventricular thickening on echocardiography without a clear history of hypertension
should point towards inﬁltrative cardiomyopathy.
 Troponin and N-terminal pro-B-type natriuretic
peptide elevation has a prognostic value in cardiac amyloidosis.
 Cardiac magnetic resonance imaging can demonstrate pathognomonic late gadolinium enhancement suggestive of amyloid heart disease.
 New treatments can slow down the progression
of disease.

2. Introduction

A

myloidosis is a rare condition, characterised by inﬁltration of insoluble misfolded proteins in the extracellular matrix of the
affected tissues. Cardiac involvement is the most
important factor inﬂuencing the prognosis in the
multisystem disease. The condition remains
largely underdiagnosed, particularly in the
elderly population where most of the literature on
its prevalence and progression comes from the
postmortem studies [1]. With the advent of new
and speciﬁc treatment options and ongoing clinical trials, it is important to raise awareness
amongst clinicians about this important disease
entity [2].

Received 17 July 2019; revised 12 September 2019; accepted 27 September 2019.
Available online 17 April 2020
* Corresponding author at: Division of Cardiovascular Sciences, University of Manchester, Manchester M13 9PL UK.
E-mail address: tahir.nazir-2@postgrad.manchester.ac.uk (T. Nazir).

https://doi.org/10.37616/2212-5043.1016
2212-5043/© 2020 Saudi Heart Association. This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Fig. 1. Transthoracic echocardiogram (four chamber view) showing
generalised thickening of ventricular walls and echo-bright myocardium
of the interventricular septum (arrow). LA ¼ left atrium; RA ¼ right
atrium; LV ¼ left ventricle; RV ¼ right ventricle.

3. Case report
An 84-year-old man was seen in the cardiology
outpatient clinic with chest tightness, exertional
dyspnoea, and abdominal distension. His past
medical history included dyslipidaemia and
myocardial infarction 5 years ago, for which he had
percutaneous coronary intervention and stent
insertion to the left circumﬂex artery. He was an exsmoker and did not drink alcohol. His usual medications included aspirin, bisoprolol, ramipril, and
atorvastatin.
On examination, his heart rate was 60 beats/min
and his blood pressure was 126/84 mmHg. He had
mild pedal oedema and elevated jugular venous
pressure. Heart sounds were normal and chest was
clear to auscultation. Abdominal examination
revealed a palpable liver edge and moderate ascites.
An electrocardiogram showed the sinus rhythm PR
interval prolonged to 240 ms (normal range
120e200 ms) and no other abnormality. Routine
blood tests revealed normal full blood count, renal,
and thyroid function tests. Serum glucose was
5.7 mmol/L and haemoglobin A1c was 31 mmol/
mol. Liver function tests showed normal levels of
bilirubin, albumin, and transaminases; alkaline
phosphatase and gamma-glutamyl transferase were
mildly elevated. N-terminal pro-B-type natriuretic
peptide (NT-proBNP) was elevated at 6500 ng/L
(normal <450 ng/L). An abdominal ultrasound scan
conﬁrmed hepatomegaly and a moderate amount of
ascites. Diagnostic ascitic aspiration revealed it to be
a transudate with albumin levels of 16 mg/L.
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Autoimmune and viral liver screen was negative. An
echocardiogram showed normal sized left ventricle
with moderate concentric hypertrophy and severe
diastolic dysfunction (Fig. 1). The aortic valve had
mild calciﬁcation with a normal valve area and
forward ﬂow velocity. The right ventricle was mildly
dilated with normal systolic function. Estimated
pulmonary artery systolic pressure was elevated at
77 mmHg. A trivial global pericardial effusion was
also noted. CT scans of the thorax, abdomen, and
pelvis showed no evidence of pulmonary embolism,
signiﬁcant lung disease, or malignancy. Serum and
urine immunoglobulin electrophoresis found no
abnormal bands and light chain assay was normal.
The patient was commenced on ﬂuid and salt restriction, loop diuretics, and mineralocorticoid receptor antagonist which led to an improvement in
his ascites, peripheral oedema, and shortness of
breath. A coronary angiogram revealed no signiﬁcant abnormality. Cardiac magnetic resonance imaging (MRI) showed moderate generalised
thickening of the left and right ventricular walls,
moderate bi-atrial enlargement, preserved systolic
function, severe diastolic dysfunction, and bilateral
pleural effusions (Fig. 2). Late post contrast images
revealed multiple areas of diffuse circumferential
gadolinium enhancement in both the left and right
ventricular walls, highly indicative of amyloidosis
(Fig. 3). Genetic testing did not show transthyretin
(TTR) gene mutation. Endomyocardial biopsy
revealed deposition of amyloid protein in the cardiac muscles. These ﬁndings conﬁrmed the diagnosis of senile wild type TTR amyloidosis. His
symptoms improved with conventional heart failure
medications. He is currently being assessed for the
use of diﬂunisal, which is a salicylic acid derivative
known to slow down the progression of senile wildtype TTR amyloidosis.

4. Discussion
Based upon the type of inﬁltrating protein,
amyloidosis can be divided into three groups,
namely, light chain (AL) amyloidosis, hereditary
amyloidosis (usually due to a mutation in TTR), and
senile systemic amyloidosis (deposition of wild-type
TTR monomers) [3]. Isolated atrial amyloidosis and
secondary systemic amyloidosis are also seen. A
recent autopsy study showed approximately 5% of
elderly patients with heart failure with preserved
ejection (HFpEF) have moderate to severe amyloid
inﬁltration in their left ventricle [4]. The incidence of
wild-type TTR amyloidosis in hospitalised elderly
patients with HFpEF has been reported to be
around 13% on scintigraphy [5].
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Fig. 2. Cardiac magnetic resonance imaging scan (steady state free
procession image) reveals diffuse thickening of the left ventricular wall
(arrow). LV ¼ left ventricle; RV ¼ right ventricle.

Fig. 3. Cardiac magnetic resonance imaging scan (late gadolinium
enhancement image) shows subendocardial areas of late gadolinium
enhancement in the left ventricle (LV) free wall suggestive of myocardial
inﬁltration with amyloid. Further, diffuse late gadolinium enhancement
areas can be seen in the right ventricle (RV) wall, too.

Cardiac amyloidosis leads to progressive thickening and stiffening of the ventricular walls resulting in poor ﬁlling and patients present with
symptoms of congestive heart failure including
breathlessness and fatigue [6]. The signs of right
ventricular failure, for example oedema, raised jugular venous pressure, hepatomegaly, and ascites
predominate the clinical picture. In addition, features of systemic amyloidosis, for example macroglossia, periorbital purpura, petechial rash on the
eyelids, carpal tunnel syndrome, autonomic neuropathy, cuta laxa, nail dystrophy, and weight loss,
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may also be present. Neuropathy is common in the
hereditary variant, which can present with neurological manifestations only, despite signiﬁcant cardiac involvement on imaging and histology [7]. AL
amyloidosis tends to affect kidneys and can cause
heavy proteinuria.
Standard laboratory investigations including full
blood count, renal and liver function tests, and inﬂammatory markers form an essential component
of the initial assessment. Immunoglobulin electrophoresis and serum free light chain assay can help
detect circulating paraproteins. Elevation of speciﬁc
cardiac biomarkers troponin and NT-proBNP usually points towards the presence of heart failure and
is associated with poor outcomes [8]. Genetic testing
may reveal mutations in the TTR gene in hereditary
cases.
An electrocardiogram may be completely normal
but can show low electrical voltage, AV conduction
blocks, and arrhythmias. Atrial ﬁbrillation and
ﬂutter are common ﬁndings in those with inﬁltration of the atria. A pseudo-infarct pattern with Q
waves and a loss of R waves in the precordial lead is
also seen in some patients [9].
Echocardiography is a readily available noninvasive imaging modality that can offer useful clues
towards the diagnosis which include increased
thickness of the myocardium, a restrictive ﬁlling
pattern, and diastolic dysfunction with reduced
cavity size. Bi-atrial enlargement, valve thickening,
and pericardial effusion are also present in a signiﬁcant proportion of patients.
Cardiac MRI offers the advantage of accurate
structural measurements including ventricular walls
and volumes, atrial size, and septal thickness,
combined with tissue characterisation with late
gadolinium enhancement and serves as an investigation of choice. Global subendocardial late gadolinium enhancement is considered to be the
pathognomonic pattern in cardiac amyloidosis,
however, localised, diffuse, and transmural patterns
have also been reported [10].
Cardiac heart catheterisation is reserved for
selected cases. Histological conﬁrmation of amyloid deposits is required to tailor a speciﬁc treatment strategy and remains the gold standard to
make the diagnosis [11]. In patients with systemic
disease, subcutaneous fat and rectal mucosa may
lend themselves for easy-to-access biopsy sites,
while in those with focal cardiac disease, an
endomyocardial biopsy is required [12]. Amyloid
ﬁbrils are detected with Congo red staining and
further conﬁrmed by their typical apple green
birefringence under polarised light. However,
there is some evidence that in patients with no

evidence of monoclonal gammopathy, the diagnosis of cardiac amyloidosis can be reliably made
by using bone scintigraphy without the need of
biopsy [13].
General treatment for cardiac amyloidosis is
aimed at managing the heart failure. Initial treatment with loop diuretics and mineralocorticoid receptor blockers leads to symptomatic improvement
[14]. Patients with concurrent autonomic neuropathy are at high risk of postural hypotension and
need close monitoring. Angiotensin-convertingenzyme inhibitors, angiotensin receptor blockers,
and beta blockers are usually poorly tolerated in
cardiac amyloidosis.
Atrial ﬁbrillation in patients with cardiac
amyloidosis is often poorly tolerated due to a rapid
ventricular rate, irregular ventricular ﬁlling, and
the loss of atrial contractility [15]. Rhythm control
with amiodarone or catheter ablation, along with
anticoagulation due to a high risk of embolisation,
is a preferred choice. The risk of sudden death in
patients with cardiac amyloidosis has been reported as high as 60% [16]. The risk is high in those
with a history of light chain disease and syncope.
An implantable cardiac deﬁbrillator may be
considered in those at highest risk [17]. Cardiac
transplantation may be eventually needed for endstage disease.
Speciﬁc treatments targeting the molecular
mechanisms underpinning amyloid synthesis and
deposition are available for some of the subtypes.
These include bortezomib, dexamethasone, cyclophosphamide, lenalidomide, humanised monoclonal antibodies, and stem cell transplantation for
AL amyloidosis and tafamidis, doxycyline, diﬂunisal, and patisiran for TTR-related amyloidosis [18].
Diﬂunisal is a nonsteroidal anti-inﬂammatory drug
(NSAID) that has been shown to stabilise TTR
tetramer both in vitro and in vivo [19]. In a carefully
selected subgroup of older adults with biopsy
proven ATTR cardiac amyloidosis, diﬂunisal is well
tolerated and leads to a reduction in heart failurerelated hospitalisations and improved survival
[20,21]. Patients with hypersensitivity to NSAIDs,
active or recent gastrointestinal bleeding, signiﬁcant
renal dysfunction, and expected survival less than
12 months were excluded from these trials [22].
Concurrent use of dual antiplatelets, NSAIDS, and
anticoagulants are other contraindications to the use
of diﬂunisal. The prognosis for untreated amyloid
heart disease is poor; advancing age, elevated cardiac biomarkers (troponin T/NT-proBNP), pleural
effusion, right ventricle systolic pressure, and right
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ventricular strain are important predictors of mortality [23].

5. Conclusion
Amyloidosis is a rare inﬁltrative disorder that can
involve the heart resulting in severe cardiac failure
with preserved ejection fraction; however, the condition remains underdiagnosed, particularly in
older patients. A cardiac MRI scan with late gadolinium enhancement is a useful tool to establish the
diagnosis. In an era of expanding treatment options
for cardiac amyloidosis, delayed diagnosis is one of
the most important factors leading to poor clinical
outcomes [24].
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